Abstract
Background/Objectives: Adenomyosis (AM) is a hormone-dependent gynecological disorder that negatively impacts the quality of life and fertility of reproductive-age women. This study aimed to evaluate the effectiveness of herbal medicine (HM) as a post-treatment strategy following high-intensity focused ultrasound (HIFU) therapy. Methods: English, Chinese, and Korean databases were systematically searched up to 24 March 2025. Eligible randomized controlled trials (RCTs) compared HM administration after HIFU therapy with HIFU therapy alone. Statistical analyses included mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with 95% confidence intervals (CIs). Evidence quality was assessed using GRADE approach. The protocol was registered with INPLASY (No.: INPLASY202530088). Results: Fourteen RCTs involving 1259 patients were included in the review. HM administration after HIFU therapy showed superior efficacy over HIFU therapy alone in reducing uterine volume (MD = -11.84, 95% CI: -13.74 to -9.95; p < 0.00001), adenomyotic lesion volume (MD = -2.86, 95% CI: -3.29 to -2.43; p < 0.00001), serum CA125 levels (SMD = -1.49, 95% CI: -2.41 to -0.58; p < 0.00001), serum estradiol (E2) levels (SMD = -1.28, 95% CI: -1.54 to -1.03; p < 0.0001), and improvements in dysmenorrhea (MD = -0.54, 95% CI: -1.06 to -0.02; p < 0.00001) Conclusions: HM may be an effective and safe adjunct to HIFU for managing AM. However, further high-quality RCTs with long-term follow-up are needed to validate these findings.